Apotex Granted Summary Judgment In US Pennsaid 2% Infringement Suit
Delaware District Court Case Involved Licensing Deal Signed In 2013
Apotex has decisively overcome Horizon’s patent infringement suit stemming from its launch of a generic version of the originator’s Pennsaid 2%.
You may also be interested in...
Unsatisfied with a US Court of Appeals upholding a ruling in favor of Teva's Actavis that several Pennsaid 2% patents were invalid, Horizon Therapeutics sought to have the case reheard en banc. However, the request has been refused.
Ahead of wrapping up a Phase III clinical trial for its proposed biosimilar denosumab candidate later this year, mAbxience has out-licensed marketing rights in Korea to local player HK inno.N, with a patent expiry opportunity in 2025.
Generics Bulletin looks back at a selection of the most significant legal stories from 2022, including a major victory in the UK on the Eliquis blood thinner giant and continued action on generic label carve outs, which has the potential to reverberate through the US industry.